Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
Status
Conditions
Treatments
Details and patient eligibility
About
For post-menopausal women diagnosed with hormone-receptor positive breast cancer tumors, aromatase inhibitors (AIs) are the standard adjuvant hormone treatment to prolong disease-free survival and time-to-recurrence. Unfortunately, joint pain/stiffness/achiness (arthralgia) is a common side-effect of AIs. This "proof-of-concept" study explores how an evidence-based physical activity (PA) program- the Arthritis Foundation's Walk with Ease (WWE) program- can be adapted for breast cancer survivors on AI therapy to: 1) Help them maintain or achieve recommended levels of PA, 2) reduce their joint pain/stiffness/achiness, and 3) thereby enable them to remain on AI therapy as prescribed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Taking an aromatase inhibitor as adjuvant treatment for State I, II, or II breast cancer for at least 4 weeks
- Experiencing more than mild joint pain/symptoms
- 21 or older
- have permission from physician to engage in moderate intensity physical activity
Exclusion criteria
- Undergoing chemotherapy and/or radiation therapy at any time during the study period
- Scheduled for major surgery during the study period
- Presently engaged in high levels of physical activity on a daily basis
- Less than 21 years of age
- Unable to walk or engage in moderate intensity physical activity
Trial design
Primary purpose
Allocation
Interventional model
Masking
78 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal